| Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 … C Cai, S Chen, P Ng, GJ Bubley, PS Nelson, EA Mostaghel, B Marck, ... Cancer research 71 (20), 6503-6513, 2011 | 503 | 2011 |
| Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non‐small cell lung cancer YK Chae, AA Davis, S Agte, A Pan, NI Simon, WT Iams, MR Cruz, ... The oncologist 24 (6), 820-828, 2019 | 108 | 2019 |
| Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor Z Yu, C Cai, S Gao, NI Simon, HC Shen, SP Balk Clinical cancer research 20 (15), 4075-4085, 2014 | 102 | 2014 |
| Discovery of a selective irreversible BMX inhibitor for prostate cancer F Liu, X Zhang, E Weisberg, S Chen, W Hur, H Wu, Z Zhao, W Wang, ... ACS Chemical Biology 8 (7), 1423-1428, 2013 | 53 | 2013 |
| Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA). AA Davis, YK Chae, S Agte, A Pan, NI Simon, TJ Taxter, A Behdad, ... Journal of Clinical Oncology 35 (15_suppl), e23028-e23028, 2017 | 28 | 2017 |
| Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases S Chen, X Jiang, CA Gewinner, JM Asara, NI Simon, C Cai, LC Cantley, ... Science signaling 6 (277), ra40-ra40, 2013 | 28 | 2013 |
| In Silico Discovery of Androgen Receptor Antagonists with Activity in Castration Resistant Prostate Cancer HC Shen, K Shanmugasundaram, NI Simon, C Cai, H Wang, S Chen, ... Molecular Endocrinology 26 (11), 1836-1846, 2012 | 25 | 2012 |
| Best approaches and updates for prostate cancer biochemical recurrence NI Simon, C Parker, TA Hope, CJ Paller American Society of Clinical Oncology Educational Book 42, 352-359, 2022 | 24 | 2022 |
| BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer S Chen, C Cai, AG Sowalsky, H Ye, F Ma, X Yuan, NI Simon, NS Gray, ... Cancer research 78 (18), 5203-5215, 2018 | 23 | 2018 |
| Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation X Liu, W Han, S Gulla, NI Simon, Y Gao, C Cai, H Yang, X Zhang, J Liu, ... Oncotarget 7 (2), 1754, 2016 | 23 | 2016 |
| Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy YK Chae, WB Kim, AA Davis, LC Park, JF Anker, NI Simon, K Rhee, ... Translational lung cancer research 9 (4), 1015, 2020 | 15 | 2020 |
| Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors T El Zarif, AH Nassar, GR Pond, TZ Zhuang, V Master, B Nazha, S Niglio, ... JNCI: Journal of the National Cancer Institute 115 (12), 1605-1615, 2023 | 13 | 2023 |
| Evolving role of adjuvant systemic therapy for kidney and urothelial cancers AB Apolo, P Msaouel, S Niglio, N Simon, E Chandran, D Maskens, ... American Society of Clinical Oncology Educational Book 42, 311-326, 2022 | 11 | 2022 |
| Androgen ablation elicits PP1‐dependence for AR stabilization and transactivation in prostate cancer X Liu, W Han, S Gulla, NI Simon, Y Gao, J Liu, L Wang, H Yang, X Zhang, ... The Prostate 76 (7), 649-661, 2016 | 9 | 2016 |
| A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects. E Chandran, NI Simon, SA Niglio, L Ley, LM Cordes, R Banday, ... Journal of Clinical Oncology 41 (16_suppl), TPS4607-TPS4607, 2023 | 3 | 2023 |
| Efficacy of anti-PD (L) 1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC). TF Stewart, NV Kotha, HE Dzimitrowicz, D Makrakis, AR Khaki, NI Simon, ... Journal of Clinical Oncology 39 (15_suppl), e16515-e16515, 2021 | 2 | 2021 |
| Circulating tumor DNA (ctDNA) as a marker of minimal residual disease (MRD) in localized non-small cell lung carcinoma (NSCLC). NI Simon, AA Davis, NA Mohindra, VM Villaflor, YK Chae Journal of Clinical Oncology 36 (15_suppl), 8550-8550, 2018 | 2 | 2018 |
| A phase II study of lurbinectedin with or without avelumab in small cell carcinoma of the bladder (LASER). NI Simon, E Chandran, SA Niglio, AR Kydd, SO Atiq, L Ley, T Wang, ... Journal of Clinical Oncology 42 (16_suppl), TPS4629-TPS4629, 2024 | 1 | 2024 |
| Mismatch repair deficiency and Microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis EBA Chandran, GM Iannantuono, SO Atiq, D Akbulut, N Sinaii, NI Simon, ... BMJ Oncology 3 (1), 2024 | 1 | 2024 |
| A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU … NI Simon, SA Niglio, E Chandran, GM Iannantuono, S Boudjadi, ... Journal of Clinical Oncology 41 (16_suppl), 4571-4571, 2023 | 1 | 2023 |
